<p>Qualigen Therapeutics Inc. held a Special Meeting of Stockholders on November 16, 2025. Stockholders approved all proposals, including the Subscription Agreement authorizing issuance of 337,432 common shares and 39,943 Series B convertible preferred shares, approval to exceed the 19.99% issuance threshold, and the 2025 Equity Incentive Plan with an evergreen provision. Faraday Future was confirmed as the new majority and controlling shareholder. The meeting also authorized potential adjournment for additional voting matters. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qualigen Therapeutics Inc. published the original content used to generate this news brief on November 16, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here</p>

QLGN

AIXC

<p>Qualigen Therapeutics Inc. held a Special Meeting of Stockholders on November 16, 2025, approving all proposals including issuance of shares, exceeding issuance threshold, and the 2025 Equity Incentive Plan. Faraday Future became the new majority shareholder. The meeting allowed for potential adjournment for further voting.</p>

Qualigen Therapeutics Inc. held shareholder meeting